|Company Name||Tesaro, Inc.|
On January 12, 2018, Tesaro announced that it had updated the U.S. labeling for Varubi (rolapitant), indicated for the prevention of delayed nausea and vomiting associated with chemotherapy, after receiving reports of "[a]naphylaxis, anaphylactic shock and other serious hypersensitivity reactions . . . in the postmarketing setting, some requiring hospitalization." The Company further disclosed that it "has issued a Dear Healthcare Professional (DHCP) letter."
On this news, shares of Tesaro fell $3.73 or 5.4%, to close at $65.86 on January 16, 2018, thereby injuring investors.
Submit Your Information
If you suffered a loss on your Tesaro, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below.
An attorney will contact you at no cost to provide you information about joining the action and answer your questions. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.